Alder BioPharmaceuticals to Host Conference Call to Discuss

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2016 Financial and Operating Results

BOTHELL, Wash., April 21, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its first quarter 2016 financial and operating results after the close of U.S. financial markets on Thursday, April 28, 2016. Alder management will host a conference call and live audio webcast to discuss the results and provide a general business update at 5:00 p.m. ET the same day.

The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers, and providing conference ID number 87888909. The webcast will be accessible on the Events & Presentations page of the Investors section of Alder’s website at  www.alderbio.com and will be available for replay following the call for 30 days.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. ALD403, Alder's lead pivotal-stage product candidate being evaluated for migraine prevention, is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). CGRP is a small protein with a well-established role in the initiation, transmission and heightened sensitivity to migraine pain. Alder's second program, ALD1613, targets adrenocorticotropic hormone (ACTH) and is intended for the treatment of congenital adrenal hyperplasia and Cushing's disease. ALD1613 is undergoing Investigational New Drug (IND)-enabling preclinical studies, and an IND submission is planned for 2016. Additionally, Alder's clazakizumab is designed to block the pro-inflammatory cytokine IL-6 and has completed two successful Phase 2b clinical trials. Alder is seeking strategic opportunities for clazakizumab. For more information, please visit  http://www.alderbio.com . 

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements relating to: the continued development and clinical, therapeutic and commercial potential of ALD403, ALD1613 and clazakizumab; future regulatory filings; and the pursuit of strategic opportunities for clazakizumab. Words such as "potential," "intended," "planned," "seeking," or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Alder's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: risks related to the potential failure of ALD403, ALD1613 and clazakizumab to demonstrate safety and efficacy in clinical testing; the availability of data at the expected times; the clinical, therapeutic and commercial value of ALD403, ALD1613 and clazakizumab; risks and uncertainties related to regulatory review and approval processes and Alder's compliance with applicable legal and regulatory requirements; and other factors discussed under the caption "Risk Factors" in Alder's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which was filed with the Securities and Exchange Commission (SEC) on February 23, 2016, and is available on the SEC's website at www.sec.gov . Additional information will also be set forth in Alder's other reports and filings it will make with the SEC from time to time.  The forward-looking statements made in this press release speak only as of the date of this press release.  Alder expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Alder's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts: David Schull or Lena Evans Russo Partners (212) 845-4271 (212) 845-4262 david.schull@russopartnersllc.com lena.evans@russopartnersllc.com Investor Relations Contact: David Walsey Alder Biopharmaceuticals Inc.. (425) 408-8032 ir@alderbio.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 157

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 79

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 91

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 227

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 127

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 25

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 159

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 42

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 182

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading

Top 5 Most Recently Viewed Articles

TRUBAR Inc. Takes Bold Steps with Personal Care Product Sale

Updated Category News Views 169

TRUBAR Inc. Streamlines Focus with Recent Asset Sale TRUBAR Inc. is making significant moves to streamline its operations and focus on its core identity as a leading provider of plant-based protein products. The company has announced that it has successfully sold the assets related to its personal care product line through its subsidiary, NO BS Life, LLC. This strategic...

Continue Reading
Advancements in Squamous Cell Carcinoma Treatments Unveiled

Updated Category News Views 362

Examining Treatments for Squamous Cell Carcinoma The landscape of squamous cell carcinoma (SCC) treatments is rapidly evolving. This shift is largely driven by the increasing number of diagnosed cases. As public awareness rises and exposure to risk factors like ultraviolet (UV) radiation continues, healthcare professionals and researchers are persistently seeking...

Continue Reading
Millennium Physician Group and IMA Medical Group Unite for Better Care

Updated Category News Views 327

Millennium Physician Group and IMA Medical Group Unite for Better Patient Care In an exciting development for healthcare in Central Florida, Millennium Physician Group has announced its collaboration with IMA Medical Group. This partnership represents a major step forward in expanding value-based, patient-centered care to the local communities. About the New Partnership...

Continue Reading
Innovative Partnership to Revolutionize Osteoporosis Detection

Updated Category News Views 96

Strategic Alliance to Enhance Osteoporosis Awareness Naitive Technologies Ltd., a leader in population health innovation focused on musculoskeletal care, has embarked on an important partnership with Parvizi Surgical Innovation (PSI). This collaboration aims to significantly improve the detection and clinical management of osteoporosis, particularly through the use of...

Continue Reading
Storm and Fire Survivors Unite at U.S. Capitol for Aid

Updated Category News Views 451

Storm and Fire Survivors Unite at U.S. Capitol for Aid Recently, over fifty storm and fire survivors convened at the U.S. Capitol to advocate for robust disaster relief and a more effective recovery system for affected families and communities, in an event organized by Organizing Resilience. These brave individuals came together to share their compelling stories,...

Continue Reading